ClinicalTrialsFinder
RecruitingPhase 2NCT07537400

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Phase II Trial of Naxitamab, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Combination With Induction Chemotherapy for Patients With Newly-Diagnosed High-Risk Neuroblastoma

Sponsor

Shaare Zedek Medical Center

Enrollment

10 participants

Start Date

Jun 23, 2026

Study Type

INTERVENTIONAL

Conditions

High Risk Neuroblastoma

Summary

This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.

Eligibility

Min Age: 12 MonthsMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Naxitamab for people with high risk neuroblastoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Months to 21 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNaxitamab

Naxitamab and GM-CSF administered with COG type induction chemotherapy.

Locations(1)

Shaare Zedek Medical Center

Jerusalem, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07537400

Related Trials

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

NCT075493215 locations

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

NCT065284961 location

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT060579487 locations

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT066076921 location

Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

NCT064805261 location